Business & Finance
Horizon Therapeutics, Halozyme Therapeutics Enter Global Collaboration and License Agreement for Enhanze Technology
25 November 2020 - - Ireland-based Horizon Therapeutics plc (NASDAQ: HZNP) and US-based biopharmaceutical company Halozyme Therapeutics, Inc. (NASDAQ: HALO) have entered a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's Enhanze drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R, the companies said.

Horizon said it plans to use Enhanze to develop a SC formulation of Tepezza (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressive and vision-threatening rare autoimmune disease, potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.

Under the terms of the agreement, Horizon will make an upfront payment of USD 30m to Halozyme and is obligated to make potential future payments of up to USD 160m in the aggregate, subject to achievement of specified development, regulatory and sales-based milestones.

Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialized medicines using the Enhanze technology.

Horizon represents Halozyme's tenth global collaboration and license partner for the Enhanze technology.

These collaborations cover more than 50 therapeutic targets and include five commercialized products to date.

Halozyme's proprietary Enhanze drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20).

rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin).

By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. Enhanze may also benefit subcutaneous biologics by reducing the need for multiple injections.

This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.

Horizon is focused on researching, developing and commercialising medicines that address critical needs for people impacted by rare and rheumatic diseases.

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.

Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success.

Halozyme has licensed its Enhanze technology to pharmaceutical and biotechnology companies.

Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with Enhanze. Halozyme is headquartered in San Diego.